Nate Hill, co-founder & CEO, Strive, notes the key milestone to watch for during the remaining step in FDA's formal Category ...
Recently, Pharmaceutical Executive spoke with Christian Thienel, director at Back Bay Life Sciences, about the ongoing issues ...
Pharmaceutical Executive recently spoke with Mark Cziraky, president of Carelon Research. The company just signed a deal with ...
Melanie Whittington, managing director and head of the Leerink Center for Pharmacoeconomics, joins Ron Lanton to argue that ...
Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with ...
Novartis instituted program-wide clinical holds across eight Rap‑cel autoimmune trials after three IEC‑HS events with fatal outcomes, prompting regulator engagement and comprehensive cross-program ...
Simcere Zaiming has licensed its first-in-class tri-specific CD79a/CD19/CD3 T-cell engager Sim0660 to Roche for up to $1.53 ...
Nate Hill, Co-Founder & CEO of Strive Pharmacy, describes how the company approaches uncertainty around peptide inventory, ...
Eli Lilly & Company and Merida Biosciences announced a definitive agreement for Eli Lilly to acquire Merida, to advance ...
Real-world evidence tells you what happened. Real-World iNSIGHTS tell you why — and what to do next. A new framework for medical affairs. As the healthcare community grapples with rising obesity rates ...
The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA ...
Carelon Research's Mark Cziraky on why the industry's need for deeper, linked data is driving a shift toward trusted research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results